Tag: Clinical Trial

Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria

—No difference in adverse events, clinical benefit, OS for patients with or without waivers

June 27, 2024 9:00 am

by Charles Bankhead

Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.

Patients who received waivers had a clinical benefit rate … Read more

Platinum-resistant ovarian cancer: mirvetuximab soravtansine benefits are maintained in patients who require dose modifications

June 20, 2024 9:00 am

As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more

Achieving High-Quality Care for Patients With Ovarian Cancer

June 10, 2024 9:00 am

Clearity’s Perspective: This article highlights that some people with ovarian cancer who live in certain geographic locations, like rural areas, may get treated at centers with less experience treating ovarian cancer and/or fewer resources to support whole-person needs. Clearity offers … Read more

Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers

June 4, 2024 9:00 am

by Wayne Kuznar

CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more

No Benefit to Adding Atezolizumab to Chemo/Bevacizumab for Ovarian Cancer

June 2, 2024 9:00 am

by Silas Inman

The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more

Advanced Ovarian Cancer: Can Lymphadenectomy Be Avoided for Some Patients?

June 2, 2024 9:00 am

by The ASCO Post Staff

Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented … Read more

New Approach May Help People with Cancer Better Manage Depression, Pain, and Fatigue

May 14, 2024 9:00 am

Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be … Read more

Yoga shows ‘most improvement’ in restoring brain health in long-term cancer survivors, Northeastern researcher says

May 10, 2024 9:00 am

by Cynthia McCormick Hibbert

For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”

A newly published study by a Northeastern professor says that yoga might hold the key to … Read more

New FDA Guidance Looks to Improve Clinical Trial Enrollment and Diversity

April 30, 2024 9:00 am

by Sabrina Serani

The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.

While the FDA notes … Read more

Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers

— About half of patients responded, duration of response as long as 19 months in three trials

April 5, 2024 9:00 am

By Charles Bankhead

The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.

The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.

January 30, 2024 9:00 am

Clearity’s Perspective: Most drugs are tested and approved to treat cancers based on where in the body the cancer started and the type of tissue from which it developed. Enhertu (Trastuzumab Deruxtecan, T-Dxd), a HER2-targeted antibody drug conjugate (ADC), already … Read more

NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

January 19, 2024 9:00 am

Clearity’s Perspective: In the January 17, 2024 update to the National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer, several new therapies have been added to the list of acceptable regimens for recurrent platinum-resistant ovarian cancer. For example, trastuzumab deruxtecan … Read more

Gynecologic cancer clinical trial enrollment lower for certain underrepresented groups

December 29, 2023 9:00 am

By Erin T. Welsh, MA

Key takeaways:

  • Clinical trial enrollment was lower for Asian, Black and Hispanic women vs. white women.
  • Asian and Hispanic women were underrepresented in endometrial, cervical and ovarian cancer trials.

Asian, Black and Hispanic women with … Read more

Trial Analyzing MEK Inhibitor Combo for Ovarian Cancer Subset Begins

December 21, 2023 9:00 am

By Ashley Chan

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more

Psilocybin May Help Ease Depression in Cancer Patients

In small trial, half had early remission of depressive symptoms after psilocybin-assisted therapy

December 18, 2023 9:00 am

By Diana Swift

Psilocybin-assisted therapy in a group setting was safe and appeared effective in patients with cancer and depression, according to a small, phase II, open‐label trial.

After one dose of psilocybin among 30 patients, depression severity scores dropped … Read more

Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer

December 15, 2023 9:00 am

By Edward Winstead

For people being treated for cancer, participating in virtual mind–body fitness classes may have important benefits, such as reducing the risk of being hospitalized for treatment-related problems, according to results from a clinical trial.

In the trial, … Read more

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

December 6, 2023 9:00 am

By James H. Doroshow, M.D.

More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision

… Read more

PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.

November 27, 2023 9:00 am

By Kyle Doherty

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity. With the initiation of the phase … Read more

Raludotatug Deruxtecan Elicits Early Efficacy and Safety in Platinum-Resistant Ovarian Cancer

November 17, 2023 9:00 am

Clearity’s Perspective: A phase I clinical trial studying the antibody-drug conjugate (ADC) raludotatug deruxtecan (DS-6000a, R-DXd) shows early encouraging activity in heavily pretreated ovarian cancer. The antibody portion of raludotatug deruxtecan targets CDH6 (found in about 65-85% of ovarian cancers) … Read more

RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer

November 5, 2023 9:00 am

Clearity’s Perspective: The combination of avutometinib and defactinib has shown encouraging activity in Low-Grade Serous Ovarian Cancer. Updated results from the RAMP 201 trial suggest that the combination is active regardless of the number of prior therapies patients have received. … Read more